NASDAQ : CTY
City Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 20.71 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.03B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.04B |
| Enterprise Value | 931.33M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 19, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 49.76M |
| Shares Outstanding | 49.76M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 7.91% |
| Owned by Institutions (%) | 7.85% |
| Float | 24.10M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 71.85 |
| Forward PS | n/a |
| PB Ratio | 8.29 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 64.00 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.71 |
| Quick Ratio | 2.70 |
| Debt / Equity | 0.46 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -27.18 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -58.71% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $191,227 |
| Profits Per Employee | -$1.17M |
| Employee Count | 75 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | n/a |
| Average Volume (20 Days) | 350,884 |
Shortselling
| Measure | Value |
|---|
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Incomestatement
| Measure | Value |
|---|
| Revenue | 14.34M |
| Gross Profit | -66.02M |
| Operating Income | -84.46M |
| Pretax Income | -87.67M |
| Net Income | -87.67M |
| EBITDA | -83.00M |
| EBIT | -84.46M |
| Loss Per Share | -$15.72 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 169.61M |
| Total Debt | 57.04M |
| Net Cash | 112.57M |
| Net Cash Per Share | $2.26 |
| Equity (Book Value) | 124.34M |
| Book Value Per Share | -24.91 |
| Working Capital | 110.93M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -77.67M |
| Capital Expenditures | -3.08M |
| Depreciation & Amortization | 1.46M |
| Net Borrowing | n/a |
| Free Cash Flow | -80.75M |
| FCF Per Share | -$1.62 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -588.90% |
| Pretax Margin | -611.25% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -74.93% |
| FCF Yield | -7.84% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -1.59 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |